1 |
VACCARELLA S, LORTET-TIEULENT J, COLOMBET M, et al. Global patterns and trends in incidence and mortality of thyroid cancer in children and adolescents: a population-based study[J]. Lancet Diabetes Endocrinol, 2021, 9(3): 144-152.
|
2 |
HADDAD R I, NASR C, BISCHOFF L, et al. NCCN guidelines insights: thyroid carcinoma, version 2.2018[J]. J Natl Compr Canc Netw, 2018, 16(12): 1429-1440.
|
3 |
FILETTI S, DURANTE C, HARTL D, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2019, 30(12): 1856-1883.
|
4 |
CHEN P, PAN L Q, HUANG W S, et al. BRAF V600E and lymph node metastases in papillary thyroid cancer[J]. Endocr Connect, 2020, 9(10): 999-1008.
|
5 |
YU J H, DENG Y H, LIU T T, et al. Lymph node metastasis prediction of papillary thyroid carcinoma based on transfer learning radiomics[J]. Nat Commun, 2020, 11(1): 4807.
|
6 |
IBRAHIMPASIC T, GHOSSEIN R, SHAH J P,et al. Poorly differentiated carcinoma of the thyroid gland: current status and future prospects[J]. Thyroid, 2019, 29(3): 311-321.
|
7 |
AL-MASRI M, AL-SHOBAKI T, AL-NAJJAR H,et al.BRAF V600E mutation in papillary thyroid carcinoma: its relation to clinical features and oncologic outcomes in a single cancer centre experience[J]. Endocr Connect, 2021, 10(12): 1531-1537.
|
8 |
TAO Y B, WANG F, SHEN X P, et al. BRAF V600E status sharply differentiates lymph node metastasis-associated mortality risk in papillary thyroid cancer[J]. J Clin Endocrinol Metab, 2021, 106(11): 3228-3238.
|
9 |
SCHEFFEL R S, DE CRISTO A P, ROMITTI M, et al. The BRAFV600E mutation analysis and risk stratification in papillary thyroid carcinoma[J]. Arch Endocrinol Metab, 2021, 64(6): 751-757.
|
10 |
KIM K J, KIM S G, TAN J, et al. BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma[J]. Eur J Cancer, 2020, 124: 161-169.
|
11 |
ZHOU S L, GUO Y P, ZHANG L, et al. Predicting factors of central lymph node metastasis and BRAFV600E mutation in Chinese population with papillary thyroid carcinoma[J]. World J Surg Oncol, 2021, 19(1): 211.
|
12 |
JI W, XIE H, WEI B J, et al. Relationship between BRAF V600E gene mutation and the clinical and pathologic characteristics of papillary thyroid microcarcinoma[J]. Int J Clin Exp Pathol, 2019,12(9): 3492-3499.
|
13 |
XU S Y, HUANG H, QIAN J X, et al. Prevalence of hashimoto thyroiditis in adults with papillary thyroid cancer and its association with cancer recurrence and outcomes[J].JAMA Netw Open,2021,4(7): e2118526.
|
14 |
HO A S, LUU M, BARRIOS L, et al. Incidence and mortality risk spectrum across aggressive variants of papillary thyroid carcinoma[J].JAMA Oncol, 2020,6(5): 706-713.
|
15 |
ENUMAH S, FINGERET A, PARANGI S, et al. BRAFV600E mutation is associated with an increased risk of papillary thyroid cancer recurrence[J]. World J Surg, 2020, 44(8): 2685-2691.
|
16 |
ZURNADZHY L, BOGDANOVA T, ROGOUNOVITCH T I, et al. The BRAF V600E mutation is not a risk factor for more aggressive tumor behavior in radiogenic and sporadic papillary thyroid carcinoma at a young age[J]. Cancers, 2021, 13(23): 6038.
|
17 |
LAN X B, BAO H, GE X Y, et al. Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis[J]. Cancer Sci, 2020, 111(6): 2163-2173.
|
18 |
CHEN T Y, LORCH J H, WONG K S, et al. Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma[J]. Histopathology,2020,77(2): 314-320.
|
19 |
O’CONNOR E, MULLINS M, O’CONNOR D,et al. The relationship between ultrasound microcalcifications and psammoma bodies in thyroid tumours: a single-institution retrospective study[J]. Clin Radiol, 2022, 77(1): e48-e54.
|
20 |
SIPPEL R S, ROBBINS S E, POEHLS J L, et al. A randomized controlled clinical trial: no clear benefit to prophylactic central neck dissection in patients with clinically node negative papillary thyroid cancer[J]. Ann Surg, 2020, 272(3): 496-503.
|
21 |
倪洪岗, 杨 娟, 陈永华, 等.甲状腺癌细胞增殖、凋亡、迁移、侵袭的影响及其机制研究[J]. 中国实用内科杂志, 2020, 40(11): 969.
|
22 |
王 欣, 赵玉珠.促甲状腺激素与甲状腺癌发病及病理特征的关系研究[J].中国实用内科杂志, 2021, 41(5): 424-427.
|
23 |
SILVER J A, BOGATCHENKO M, PUSZTASZERI M,et al. BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm[J]. Le J D’oto Rhino Laryngol De Chir Cervico Faciale, 2021, 50(1): 63.
|
24 |
HERNANDEZ B Y, RAHMAN M, LOO L W M,et al. BRAF V600E, hypothyroidism, and human relaxin in thyroid carcinogenesis[J]. J Cancer Res Clin Oncol, 2021, 147(1): 183-194.
|
25 |
PUCCINI M, MANCA G, NERI C M, et al. Effect of sentinel node biopsy in clinically N0, BRAF V600E-mutated, small papillary thyroid carcinoma: a pilot study[J]. Clin Nucl Med, 2019, 44(5): 359-364.
|
26 |
PESSÔA-PEREIRA D, MEDEIROS M F D S, LIMA V M S,et al.Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series[J]. Arch Endocrinol Metab, 2019, 63(2): 97-106.
|
27 |
KURE S, ISHINO K, KUDO M, et al. Incidence of BRAF V600E mutation in patients with papillary thyroid carcinoma: a single-institution experience[J]. J Int Med Res, 2019, 47(11): 5560-5572.
|
28 |
LIU J J, LIU R Y, SHEN X P, et al. The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer[J]. J Nucl Med, 2020, 61(2): 177-182.
|
29 |
SAMÀ M T, GROSSO E, MELE C, et al. Molecular characterisation and clinical correlation of papillary thyroid microcarcinoma[J]. Endocrine, 2021, 71(1): 149-157.
|
30 |
DESAI J, GAN H, BARROW C, et al. Phase Ⅰ, open-label, dose-escalation/dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors[J]. J Clin Oncol, 2020, 38(19): 2140-2150.
|
31 |
ANAND D, YASHASHWI K, KUMAR N, et al. Weakly supervised learning on unannotated H&E-stained slides predicts BRAF mutation in thyroid cancer with high accuracy[J]. J Pathol, 2021, 255(3): 232-242.
|